Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

Go back to Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 52.42 -0.39 (0.74%)
Previous Close $52.81    52 Week High $45.58 
Open $52.59    52 Week Low $37.82 
Day High $52.69    P/E N/A 
Day Low $51.51    EPS $0.00 
Volume 4,011,093       

GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 52.42 -0.39 (0.74%)
Previous Close $52.81    52 Week High $45.58 
Open $52.59    52 Week Low $37.82 
Day High $52.69    P/E N/A 
Day Low $51.51    EPS $0.00 
Volume 4,011,093       

Pfizer Inc. (NYSE: PFE) Delayed: 24.08 -0.29 (1.19%)
Previous Close $24.37    52 Week High $37.39 
Open $24.43    52 Week Low $28.25 
Day High $24.46    P/E 14.59 
Day Low $23.78    EPS $1.65 
Volume 60,027,317